Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Treatment/Intervention:  sentinel lymph node biopsy
Results 1-15 of 15 for your search:
Start Over
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 10-000062, NCI-2013-00645, 11-002177, 10-001674, NCT01826864
Indocyanine Green Solution and Near-Infrared Fluorescence Imaging in Lymph Node Mapping in Patients with Stage I-II Non-small Cell Lung Cancer Undergoing Surgery
Status: Active
Phase: Phase II, Phase I
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: 05-219, NCI-2012-00260, NCT00264602
VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: VST-1001-02, NCI-2014-02431, 2013-1021, NCT02294565
Lymph Node Mapping in Finding Metastatic Disease in Patients with Sebaceous Gland Carcinoma of the Eyelid
Status: Active
Phase: Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: 2008-0266, NCI-2011-01097, NCT00832429
Letrozole with or without Ribociclib before Surgery in Treating Women with Stage II-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011XUS10T, NCI-2016-00423, STUDY00002972, NCT02712723
Lymphoseek and Lymphazurin in Detecting Lymph Nodes in Patients with Endometrial, Vulvar, or Cervical Cancer Who Are Undergoing Lymph Node Dissection
Status: Active
Phase: Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: 141163, NCI-2016-01126, HRPP141163, NCT02589366
Real-Time Near Infrared-Guided Imaging in Mapping Lymph Nodes in Patients With Melanoma Undergoing Surgery
Status: Active
Phase: Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: 10-039, NCI-2011-03688, NCT01121718
Recombinant Interferon Alfa-2b or PEG-Interferon Alfa-2b in Treating Patients With Melanoma Undergoing Sentinel Lymph Node Biopsy
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 08-067, NCI-2011-02485, NCT00871533
Observation in Patients with Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
Status: Active
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: GOG-0270, NCI-2012-00100, CDR0000721346, NCT01500512
Lymph Node Mapping in Diagnosing Patients With Endometrial Cancer
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 to 85
Trial IDs: OSU-12114, NCI-2013-00530, NCT01818739
Axillary Ultrasound with or without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 201209143, NCI-2013-00837, NCT01821768
Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery
Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: Any age
Trial IDs: CASE 9813, NCI-2013-01309, NCT01939028
Indocyanine Green Solution and Technetium Tc-99m Sulfur Colloid before Surgery in Mapping Axillary Lymph Nodes in Patients with Stage I-II Breast Cancer Undergoing Surgery
Status: Not yet active
Phase: No phase specified
Type: Diagnostic
Age: Not specified
Trial IDs: CASE10114, NCI-2015-00150, NCT02419807
Sentinel Lymph Node Biopsy in Detecting Breast Cancer That Has Spread to the Lymph Nodes in Patients Who Have Received Chemotherapy or Hormone Therapy before Surgery
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 to 75
Trial IDs: 15-494, NCI-2016-00700, NCT02752009
Intravital Microscopy in Identifying Tumor Vessels in Patients with Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy
Status: Not yet active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 18 and over
Trial IDs: I 284116, NCI-2016-01076, NCT02857374
Start Over